Last reviewed · How we verify

Perfusion of treatment Ocrelizumab

Rennes University Hospital · Phase 3 active Small molecule

Perfusion of treatment Ocrelizumab is a CD20-targeting monoclonal antibody Small molecule drug developed by Rennes University Hospital. It is currently in Phase 3 development for Relapsing forms of multiple sclerosis, Primary progressive multiple sclerosis.

Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells.

Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells. Used for Relapsing forms of multiple sclerosis, Primary progressive multiple sclerosis.

At a glance

Generic namePerfusion of treatment Ocrelizumab
SponsorRennes University Hospital
Drug classCD20-targeting monoclonal antibody
TargetCD20
ModalitySmall molecule
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

By binding to CD20, ocrelizumab triggers the depletion of B cells, which are involved in the pathogenesis of multiple sclerosis and other autoimmune diseases. This depletion leads to a reduction in disease activity and symptoms. Ocrelizumab has been shown to be effective in treating relapsing forms of multiple sclerosis and primary progressive multiple sclerosis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Perfusion of treatment Ocrelizumab

What is Perfusion of treatment Ocrelizumab?

Perfusion of treatment Ocrelizumab is a CD20-targeting monoclonal antibody drug developed by Rennes University Hospital, indicated for Relapsing forms of multiple sclerosis, Primary progressive multiple sclerosis.

How does Perfusion of treatment Ocrelizumab work?

Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells.

What is Perfusion of treatment Ocrelizumab used for?

Perfusion of treatment Ocrelizumab is indicated for Relapsing forms of multiple sclerosis, Primary progressive multiple sclerosis.

Who makes Perfusion of treatment Ocrelizumab?

Perfusion of treatment Ocrelizumab is developed by Rennes University Hospital (see full Rennes University Hospital pipeline at /company/rennes-university-hospital).

What drug class is Perfusion of treatment Ocrelizumab in?

Perfusion of treatment Ocrelizumab belongs to the CD20-targeting monoclonal antibody class. See all CD20-targeting monoclonal antibody drugs at /class/cd20-targeting-monoclonal-antibody.

What development phase is Perfusion of treatment Ocrelizumab in?

Perfusion of treatment Ocrelizumab is in Phase 3.

What are the side effects of Perfusion of treatment Ocrelizumab?

Common side effects of Perfusion of treatment Ocrelizumab include Infusion-related reactions, Infections, Neurological disorders.

What does Perfusion of treatment Ocrelizumab target?

Perfusion of treatment Ocrelizumab targets CD20 and is a CD20-targeting monoclonal antibody.

Related